A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Moderate to Severe Atopic Dermatitis.
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Desoximetasone (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Taro Pharmaceuticals USA
- 26 Jan 2018 Status changed from active, no longer recruiting to completed.
- 17 Aug 2017 Planned End Date changed from 1 May 2017 to 1 Nov 2017.
- 17 Aug 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Oct 2017.